CRISPR Gene Editing Market – A Global and Regional Analysis: Focus on Product, Application, End User, and Country-Wise Analysis – Analysis and Forecast, 2020-2031

Table of Contents

1 Technology Definition 1.1 Inclusion and Exclusion Criteria 1.1.1 Inclusions 1.1.2 Exclusions 2 Research Scope 2.1 Key Questions Answered in the Report 2.2 Target Audience 3 Research Methodology 3.1 CRISPR Gene Editing: Research Methodology 3.2 Primary Data Sources 3.3 Secondary Data Sources 3.4 Market Estimation Model 3.5 Criteria for Company Profiling 4 Market Overview 4.1 Introduction 4.2 CRISPR Gene Editing Market Approach 4.3 Milestones in CRISPR Gene Editing 4.4 CRISPR Gene Editing: Delivery Systems 4.5 CRISPR Technology: A Potential Tool for Gene Editing 4.6 CRISPR Gene Editing Current Scenario 4.7 CRISPR Gene Editing Market: Future Potential Application Areas 5 CRISPR Gene Editing Pipeline Analysis 5.1 CTX001 5.1.1 Product Profile 5.1.2 CTX001 Clinical Trial Status 5.1.2.1 Safety Profile of CTX001 5.2 EDIT-301 5.2.1 Product Profile 5.2.2 EDIT-301 Clinical Trial Status 5.2.2.1 EDIT-301 Preclinical Studies 5.3 NTLA-5001 5.3.1 Product Profile 5.3.1.1 NTLA-5001 Mechanism of Action 5.3.2 NTLA-5001 CLINICAL TRIAL STATUS 5.4 EDIT-101 5.4.1 Product Profile 5.4.2 EDIT-101 CLINICAL TRIAL STATUS 5.4.2.1 Preclinical Studies of EDIT-101 5.4.2.2 Updated Results from Ongoing Phase I/II Clinical Study 5.4.2.3 Preliminary Results of EDIT-101 5.5 OTQ923 and HIX763 5.5.1 Product Profile 5.5.2 OTQ923 and HIX763 CLINICAL TRIAL STATUS 5.6 GPH101 5.6.1 Product Profile 5.6.2 EDIT-101 CLINICAL TRIAL STATUS 5.6.2.1 Efficiency of Targeted Gene Integration 5.6.2.2 Preclinical Validation of GPH101 5.7 BD111 5.7.1 Product Profile 5.7.2 BD111 CLINICAL TRIAL STATUS 5.8 Early Stage Emerging CRISPR Therapies 6 Impact of COVID-19 on Global CRISPR Gene Editing Market 6.1 Impact of COVID-19 on Global CRISPR Gene Editing Market Growth Rate 6.2 Impact on CRISPR Gene Editing Companies 6.3 Clinical Trial Disruptions and Resumptions 6.4 Application of CRISPR Gene Editing in COVID-19 7 Market Dynamics 7.1 Impact Analysis 7.2 Market Drivers 7.2.1 Prevalence of Genetic Disorders and Use of Gene editing 7.2.2 Government and Private Funding 7.2.3 Technology Advancement in CRISPR Gene Editing 7.3 Market Restraints 7.3.1 Off-Target Effects and Delivery 7.3.2 Ethical Concerns and Implications with Respect to Human Gene editing 7.4 Market Opportunities 7.4.1 Expanding Gene and Cell Therapy Area 7.4.2 CRISPR Gene Editing Scope in Agriculture 8 Industry Insights 8.1 Introduction 8.2 Funding Scenario 8.2.1 Funding Scenario: Public Companies 8.2.2 Funding Scenario: Private Companies 8.2.3 Funding Scenario: Government Organizations 8.3 Regulatory Scenario of CRISPR Gene Editing Market 8.3.1 Overview 8.3.2 Legal Requirements and Frameworks in the U.S. 8.3.3 Clinical Trial Authorization 8.3.4 Marketing Authorization 8.3.5 USFDA Guidelines for BLA Submission 8.3.6 Post-Authorization Regulations 8.3.7 Legal Requirements and Frameworks in Europe 8.3.7.1 EMA Biologics License Application Process 8.3.7.2 Centralized Procedure 8.3.7.3 Decentralized Procedure 8.3.7.4 Mutual-Recognition Procedure 8.3.7.5 National Procedure 8.4 Legal Requirements and Frameworks in Asia-Pacific 8.4.1 Legal Requirements and Framework in Japan 8.4.2 Expedited Regulatory Designations around the World 8.5 Pricing of CRISPR Gene Editing 8.6 Reimbursement of CRISPR Gene Editing 8.6.1 CRISPR Gene Editing: Insurance Coverage in the U.S. 9 Global CRISPR Gene Editing Patent Landscape 9.1 Overview 9.2 Global CRISPR Gene Editing Market Patent Landscape (by Application) 9.3 Global CRISPR Gene Editing Market Patent Landscape (by Region) 9.4 CRISPR Gene Editing Market Patent Landscape (by Year) 10 Global CRISPR Gene Editing Market (by Product Type) 10.1 Overview 10.2 CRISPR Products 10.2.1 Kits and Enzymes 10.2.1.1 Vector-Based Cas9 10.2.1.2 DNA-Free Cas9 10.2.2 Libraries 10.2.3 Design Tools 10.2.4 Antibodies 10.2.5 Other Products 10.3 CRISPR Services 10.3.1 gRNA Design and Vector Construction 10.3.2 Cell Line and Engineering 10.3.3 Screening Services 10.3.4 Other Services 11 Global CRISPR Gene Editing Market (by Application), 11.1 Overview 11.2 Agriculture 11.3 Biomedical 11.3.1 Gene Therapy 11.3.2 Drug Discovery 11.3.3 Diagnostics 11.4 Industrial 11.5 Other Applications 12 Global CRISPR Gene Editing Market (by End User) 12.1 Academic Institutes and Research Centers 12.2 Biotechnology Companies 12.3 Contract Research Organizations (CROs) 12.4 Pharmaceutical and Biopharmaceutical Companies 13 Global CRISPR Gene Editing Market (by Region) 13.1 Introduction 13.1.1 Global CRISPR Gene Editing Market (by Region), 2020-2031 13.2 North America 13.2.1 U.S. 13.2.1.1 U.S. CRISPR Gene Editing Market (by Application), 2020-2031 13.2.2 Canada 13.2.2.1 Canada CRISPR Gene Editing Market (by Application), 2020-2031 13.3 Europe 13.3.1 U.K. 13.3.1.1 U.K. CRISPR Gene Editing Market (by Application), 2020-2031 13.3.2 Germany 13.3.2.1 Germany CRISPR Gene Editing Market (by Application), 2020-2031 13.3.3 France 13.3.3.1 France CRISPR Gene Editing Market (by Application), 2020-2031 13.3.4 Spain 13.3.4.1 Spain CRISPR Gene Editing Market (by Application), 2020-2031 13.3.5 Italy 13.3.5.1 Italy CRISPR Gene Editing Market (by Application), 2020-2031 13.3.6 Switzerland 13.3.6.1 Switzerland CRISPR Gene Editing Market (by Application), 2020-2031 13.3.7 Rest-of-Europe 13.3.7.1 Rest-of-Europe CRISPR Gene Editing Market (by Application), 2020-2031 13.4 Asia-Pacific 13.4.1 Japan 13.4.1.1 Japan CRISPR Gene Editing Market (by Application), 2020-2031 13.4.2 China 13.4.2.1 China CRISPR Gene Editing Market (by Application), 2020-2031 13.4.3 South Korea 13.4.3.1 South Korea CRISPR Gene Editing Market (by Application), 2020-2031 13.4.4 Singapore 13.4.4.1 Singapore CRISPR Gene Editing Market (by Application), 2020-2031 13.4.5 Australia 13.4.5.1 Australia CRISPR Gene Editing Market (by Application), 2020-2031 13.4.6 India 13.4.6.1 India CRISPR Gene Editing Market (by Application), 2020-2031 13.4.7 Rest-of-APAC 13.4.7.1 Rest-of-APAC CRISPR Gene Editing Market (by Application), 2020-2031 13.5 Latin America 13.5.1 Brazil 13.5.1.1 Brazil CRISPR Gene Editing Market (by Application), 2020-2031 13.5.2 Mexico 13.5.2.1 Mexico CRISPR Gene Editing Market (by Application), 2020-2031 13.5.3 Rest-of-Latin America 13.5.3.1 RoLA CRISPR Gene Editing Market (by Application), 2020-2031 13.6 Rest-of-the-World 13.6.1 Rest-of-the-World CRISPR Gene Editing Market (by Application), 2020-2031 14 Competitive Landscape 14.1 Key Developments and Strategies 14.1.1 Overview 14.1.1.1 Regulatory and Legal Activities 14.1.1.2 Synergistic Activities 14.1.1.3 Merger and Acquisition Activities 14.1.1.4 Funding Activities 14.2 Market Share Analysis 14.3 Growth Share Analysis 15 Company Profiles 15.1 Overview 15.2 Abcam, Inc. 15.2.1 Company Overview 15.2.2 Role of Abcam, Inc. in the Global CRISPR Gene Editing Market 15.2.3 Financials 15.2.4 SWOT Analysis 15.3 Applied StemCell, Inc. 15.3.1 Company Overview 15.3.2 Role of Applied StemCell, Inc. in the Global CRISPR Gene Editing Market 15.3.3 SWOT Analysis 15.4 Agilent Technologies, Inc. 15.4.1 Company Overview 15.4.2 Role of Agilent Technologies, Inc. in the Global CRISPR Gene Editing Market 15.4.3 Financials 15.4.4 R&D Expenditure 15.4.5 SWOT Analysis 15.5 Cellecta, Inc. 15.5.1 Company Overview 15.5.2 Role of Cellecta, Inc. in the Global CRISPR Gene Editing Market 15.5.3 SWOT Analysis 15.6 CRISPR Therapeutics AG 15.6.1 Company Overview 15.6.2 Role of CRISPR Therapeutics AG in the Global CRISPR Gene Editing Market 15.6.3 Financials 15.6.4 R&D Expenditure 15.6.5 SWOT Analysis 15.7 Thermo Fisher Scientific, Inc. 15.7.1 Company Overview 15.7.2 Role of Thermo Fisher Scientific, Inc. in the Global CRISPR Gene Editing Market 15.7.3 Financials 15.7.4 R&D Expenditure 15.7.5 SWOT Analysis 15.8 GeneCopoeia, Inc. 15.8.1 Company Overview 15.8.2 Role of GeneCopoeia, Inc. in the Global CRISPR Gene Editing Market 15.8.3 SWOT Analysis 15.9 GenScript Biotech Corporation 15.9.1 Company Overview 15.9.2 Role of GenScript Biotech Corporation in the Global CRISPR Gene Editing Market 15.9.3 Financials 15.9.4 SWOT Analysis 15.1 Horizon Discovery Group PLC 15.10.1 Company Overview 15.10.2 Role of Horizon Discovery Group PLC in the Global CRISPR Gene Editing Market 15.10.3 Financials 15.10.4 SWOT Analysis 15.11 Integrated DNA Technologies, Inc. 15.11.1 Company Overview 15.11.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market 15.11.3 SWOT Analysis 15.12 Merck KGaA 15.12.1 Company Overview 15.12.2 Role of Merck KGaA in the Global CRISPR Gene Editing Market 15.12.3 Financials 15.12.4 SWOT Analysis 15.13 New England Biolabs, Inc. 15.13.1 Company Overview 15.13.2 Role of New England Biolabs, Inc. in the Global CRISPR Gene Editing Market 15.13.3 SWOT Analysis 15.14 Origene Technologies, Inc. 15.14.1 Company Overview 15.14.2 Role of Origene Technologies, Inc. in the Global CRISPR Gene Editing Market 15.14.3 SWOT Analysis 15.15 Rockland Immunochemicals, Inc. 15.15.1 Company Overview 15.15.2 Role of Rockland Immunochemicals, Inc. in the Global CRISPR Gene Editing Market 15.15.3 SWOT Analysis 15.16 Synthego Corporation 15.16.1 Company Overview 15.16.2 Role of Synthego Corporation in the Global CRISPR Gene Editing Market 15.16.3 SWOT Analysis 15.17 System Biosciences LLC 15.17.1 Company Overview 15.17.2 Role of System Biosciences LLC in the Global CRISPR Gene Editing Market 15.17.3 SWOT Analysis 15.18 ToolGen, Inc. 15.18.1 Company Overview 15.18.2 Role of ToolGen, Inc. in the Global CRISPR Gene Editing Market 15.18.3 SWOT Analysis 15.19 Takara Bio 15.19.1 Company Overview 15.19.2 Role of Takara Bio in the Global CRISPR Gene Editing Market 15.19.3 Financials 15.19.4 SWOT Analysis List of Tables Table 1: CRISPR Technology Vs. Other Gene Editing Technologies Table 2: Emerging CRISPR Gene Editing Drugs Pipeline Table 3: Impact of COVID-19 on CRISPR Clinical Trials Table 4: Private Company Investments in CRISPR Gene Editing Table 5: Total Funding Received and IPO by CRISPR Gene Editing Public Companies, $Million Table 6: Funding Scenario of Government Organizations Table 7: Expedited Regulatory Designations around the World Table 8: Cost of CRISPR Editing Experiment Table 9: Cost of CRISPR Gene Editing List of Figures Figure 1: Global Total Burden of Diseases by Cause Figure 2: Global Geriatric Population by Age Figure 3: CRISPR Gene Editing: Potential Areas of Interest Figure 4: Global CRISPR Gene Editing Market (by Product Type), $Million, 2020, 2026, and 2031 Figure 5: Global CRISPR Gene Editing: Impact Analysis Figure 6: Share of Key Developments and Strategies, July 2015-November 2021 Figure 7: Global CRISPR Gene Editing Market (by Product Type), $Million, 2021 and 2031 Figure 8: Global CRISPR Gene Editing Market (by Application), $Million, 2021 and 2031 Figure 9: Global CRISPR Gene Editing Market (by End User), $Million, 2021 and 2031 Figure 10: Global CRISPR Gene Editing Market (by Region), 2021 and 2031 Figure 11: Global CRISPR Gene Editing Market Segmentation Figure 12: Global CRISPR Gene Editing Market Methodology Figure 13: Primary Research Methodology Figure 14: Bottom-Up Approach (Segment-Wise Analysis) Figure 15: Top-Down Approach (Segment-Wise Analysis) Figure 16: CRISPR/Cas Systems and Its Classification Figure 17: CRISPR Gene Editing Approach Figure 18: Key Milestones in CRISPR Gene Editing Figure 19: CRISPR Gene Editing Delivery Methods Overview Figure 20: CRISPR Gene Editing Most Potential Future Application Areas Figure 21: CRISPR Gene Editing Global Clinical Trials (by Phase), 2021 Figure 22: CRISPR Gene Editing Global Clinical Trials (by Indication), 2021 Figure 23: CRISPR Gene Editing Global Clinical Trials (by Country), 2021 Figure 24: CTX001 Manufacturing and Infusion Figure 25: CTX001 Phase I/II Clinical Trial Design for Transfusion-Dependent β-Thalassemia Figure 26: Summary of Adverse Events Figure 27: EDIT-301-Derived Red Blood Cells Demonstrate Reduced Sickling Figure 28: EDIT-301 Phase I/II Clinical Trial Design for Sickle Cell Disease Figure 29: In Vitro and In Vivo Studies for EDIT-101 Figure 30: Advantages of NTLA-5001 for Acute Myeloid Leukaemia (AML) Figure 31: NTLA-5001: Potential Best-in-Class Engineered T-Cell Therapy for AML Figure 32: NTLA-5001 Phase I/II Clinical Study Figure 33: EDIT-101 Mechanism of Action: Removing Mutation with Editing to Correct Vision Figure 34: EDIT-101 Program Overview Figure 35: EDIT-101 Phase I/II Clinical Study Figure 36: EDIT-101 Trial Design Figure 37: EDIT-101 Safety and Efficacy Tolerability Profile Figure 38: OTQ923 and HIX763 Mechanism of Action Figure 39: OTQ923 and HIX763 Phase I/II Clinical Study Figure 40: GPH101 Mode of Action Figure 41: GPH101 Phase I/II Clinical Study Figure 42: GPH101 Phase I/II CEDAR Clinical Trial Design Figure 43: BD111 Phase I/II Clinical Study Figure 44: Figure 5.5: Most Impacted Practices in CRISPR Gene Editing Figure 45: COVID-19 Impact on CRISPR Gene Editing Market Figure 46: Application of CRISPR/Cas Systems in COVID-19 Figure 47: Global CRISPR Gene Editing: Impact Analysis Figure 48: Rise in CRISPR PubMed Publications During 2012-2017 Figure 49: NIH Funding for CRISPR-Related Research, $Million, 2015-2019 Figure 50: Technological Advancement Using CRISPR Systems Figure 51: Major Ethical Concerns of CRISPR Gene Editing Figure 52: CRISPR Gene Editing Applications in Cell and Gene Therapy Figure 53: Number of Publications on CRISPR Gene Editing in Plant Gene editing with Agricultural Applications (by Region) Figure 54: Top Funded CRISPR Gene Editing Public Companies, $Million, 2015-2020 Figure 55: Top-Funded CRISPR Gene Editing Private Companies, $Million Figure 56: Clinical Trial Authorization for CRISPR Gene Editing Figure 57: Steps for Obtaining Marketing Authorization Figure 58: USFDA Review Timeline Figure 59: EMA Review Timeline Figure 60: Global CRISPR Gene Editing Market Patents (by Application) Figure 61: U.S. and China Dominated Patents (by Application) Figure 62: Global CRISPR Gene Editing Market Patents (by Region) Figure 63: Global CRISPR Gene Editing Market Patents (by Year) Figure 64: Revenue Contribution of Different Segments (by Product Type), $Million, 2020 and 2031 Figure 65: Revenue Contribution of CRISPR Products Segments, $Million, 2020 and 2031 Figure 66: Revenue Contribution of Kits and Enzymes Products Segments, $Million, 2020 and 2031 Figure 67: Global CRISPR Gene Editing Market (Kits and Enzymes, by Product), $Million, 2020-2031 Figure 68: Global CRISPR Gene Editing Market (Vector-Based Cas9, by Kits and Enzymes), $Million, 2020-2031 Figure 69: Global CRISPR Gene Editing Market (DNA-Free Cas9, by Kits and Enzymes), $Million, 2020-2031 Figure 70: Global CRISPR Gene Editing Market (Libraries, by Product), $Million, 2020-2031 Figure 71: Global CRISPR Gene Editing Market (Design Tools, by Product), $Million, 2020-2031 Figure 72: Global CRISPR Gene Editing Market (Antibodies, by Product), $Million, 2020-2031 Figure 73: Global CRISPR Gene Editing Market (Other Products, by Product), $Million, 2020-2031 Figure 74: Revenue Contribution of CRISPR Services Segments, $Million, 2020 and 2031 Figure 75: Global CRISPR Gene Editing Market (gRNA Design and Vector Construction, by Services), $Million, 2020-2031 Figure 76: Global CRISPR Gene Editing Market (Cell Line and Engineering, by Services), $Million, 2020-2031 Figure 77: Global CRISPR Gene Editing Market (Screening Services, by Services), $Million, 2020-2031 Figure 78: Global CRISPR Gene Editing Market (Other Services, by Services), $Million, 2020-2031 Figure 79: Revenue Contribution of Different Segments (by Application), $Million 2020 and 2031 Figure 80: CRISPR Gene Editing Market (Agriculture, by Application), $Million, 2020-2031 Figure 81: Revenue Contribution of Different Segments (by Biomedical), $Million, 2020 and 2031 Figure 82: CRISPR Gene Editing Market (Gene Therapy, by Biomedical), $Million, 2020-2031 Figure 83: CRISPR Gene Editing Market (Drug Discovery, by Biomedical), $Million, 2020-2031 Figure 84: CRISPR Gene Editing Market (Diagnostics, by Biomedical), $Million, 2020-2031 Figure 85: CRISPR Gene Editing Market (Industrial, by Application), $Million, 2020-2031 Figure 86: CRISPR Gene Editing Market (Other Applications, by Application), $Million, 2020-2031 Figure 87: Revenue Contribution of Different Segments (by End User), $Million, 2020 and 2031 Figure 88: CRISPR Gene Editing Market (Academic Institutes and Research Centres, by End User), $Million 2020-2031 Figure 89: CRISPR Gene Editing Market (Biotechnology Companies, by End User), $Million, 2020-2031 Figure 90: CRISPR Gene Editing Market (Contract Research Organizations, by End User), $Million, 2020-2031 Figure 91: CRISPR Gene Editing Market (Pharmaceutical and Biopharmaceutical Companies, by End User), $Million, 2020-2031 Figure 92: Global CRISPR Gene Editing Market (by Region) Figure 93: Global CRISPR Gene Editing Market (by Region), $Million, 2020 and 2031 Figure 94: Global CRISPR Gene Editing Market (by Region), $Million, 2020-2031 Figure 95: North America CRISPR Gene Editing Market, $Million, 2020-2031 Figure 96: North America: Market Dynamics Figure 97: Revenue Contributions of Various Countries in North America, 2020 and 2031 Figure 98: U.S. CRISPR Gene Editing Market, $Million, 2020-2031 Figure 99: U.S. CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 100: Canada CRISPR Gene Editing Market, $Million, 2020-2031 Figure 101: Canada CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 102: Europe CRISPR Gene Editing Market, $Million, 2020-2031 Figure 103: Europe: Market Dynamics Figure 104: Revenue Contributions of Various Countries in Europe, $Million, 2020 and 2031 Figure 105: U.K. CRISPR Gene Editing Market, $Million, 2020-2031 Figure 106: U.K. CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 107: Germany CRISPR Gene Editing Market, $Million, 2020-2031 Figure 108: Germany CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 109: France CRISPR Gene Editing Market, $Million, 2020-2031 Figure 110: France CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 111: Spain CRISPR Gene Editing Market, $Million, 2020-2031 Figure 112: Spain CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 113: Italy CRISPR Gene Editing Market, $Million, 2020-2031 Figure 114: Italy CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 115: Switzerland CRISPR Gene Editing Market, $Million, 2020-2031 Figure 116: Switzerland CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 117: Rest-of-Europe CRISPR Gene Editing Market, $Million, 2020-2031 Figure 118: Rest-of-Europe CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 119: Asia-Pacific CRISPR Gene Editing Market, $Million, 2020-2031 Figure 120: Asia-Pacific: Market Dynamics Figure 121: Revenue Contributions of Various Countries in Asia-Pacific, $Million, 2020 and 2031 Figure 122: Japan CRISPR Gene Editing Market, $Million, 2020-2031 Figure 123: Japan CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 124: China CRISPR Gene Editing Market, $Million, 2020-2031 Figure 125: China CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 126: South Korea CRISPR Gene Editing Market, $Million, 2020-2031 Figure 127: South Korea CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 128: Singapore CRISPR Gene Editing Market, $Million, 2020-2031 Figure 129: Singapore CRISPR gene editing Market (by Application), $Million, 2020-2031 Figure 130: Australia CRISPR Gene Editing Market, $Million, 2020-2031 Figure 131: Australia CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 132: India CRISPR Gene Editing Market, $Million, 2020-2031 Figure 133: India CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 134: Rest-of-APAC CRISPR Gene Editing Market, $Million, 2020-2031 Figure 135: Rest-of-APAC CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 136: Latin America CRISPR Gene Editing Market, $Million, 2020-2031 Figure 137: Latin America: Market Dynamics Figure 138: Revenue Contributions of Various Countries in Latin America, $Million, 2020 and 2031 Figure 139: Brazil CRISPR Gene Editing Market, $Million, 2020-2031 Figure 140: Brazil CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 141: Mexico CRISPR Gene Editing Market, $Million, 2020-2031 Figure 142: Mexico CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 143: RoLA CRISPR Gene Editing Market, $Million, 2020-2031 Figure 144: RoLA CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 145: Rest-of-the-World CRISPR Gene Editing Market, $Million, 2020-2031 Figure 146: Rest-of-the-World CRISPR Gene Editing Market (by Application), $Million, 2020-2031 Figure 147: Share of Key Developments and Strategies, July 2015-November 2021 Figure 148: Regulatory and Legal Developments Share (by Company), July 2015-November 2021 Figure 149: Synergistic Activities (by Company), July 2015-November 2021 Figure 150: Company Share (by Synergistic Activities), July 2015-November 2021 Figure 151: M&A Activities Share (by Company), July 2015-November 2021 Figure 152: Funding Activities (by Company), July 2015-November 2021 Figure 153: Market Share Analysis (by Company), 2019 and 2020 Figure 154: Growth Share Matrix for Global CRISPR Gene Editing Market (by Company), 2020 Figure 155: Total Number of Companies Profiled Figure 156: Abcam, Inc.: Overall Product Portfolio Figure 157: Abcam, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 158: Abcam, Inc.: Overall Financials, $Million, 2018-2020 Figure 159: Abcam, Inc.: Net Revenue (by Region), $Million, 2018-2020 Figure 160: Abcam, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 161: Abcam, Inc.: SWOT Analysis Figure 162: Applied StemCell, Inc.: Overall Product Portfolio Figure 163: Applied StemCell, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 164: Applied StemCell, Inc.: SWOT Analysis Figure 165: Agilent Technologies, Inc.: Overall Product Portfolio Figure 166: Agilent Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 167: Agilent Technologies, Inc.: Overall Financials, $Million, 2018-2020 Figure 168: Agilent Technologies, Inc. Net Revenue (by Business Segment), $Million, 2018-2020 Figure 169: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 170: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 171: Agilent Technologies, Inc.: SWOT Analysis Figure 172: Cellecta, Inc.: Overall Product Portfolio Figure 173: Cellecta, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 174: Cellecta, Inc.: SWOT Analysis Figure 175: CRISPR Therapeutics AG: Overall Product Portfolio Figure 176: CRISPR Therapeutics AG: CRISPR Gene Editing Product Portfolio Pipeline Figure 177: CRISPR Therapeutics AG: Overall Financials, $Million, 2018-2020 Figure 178: CRISPR Therapeutics AG: R&D Expenditure, $Million, 2018-2020 Figure 179: CRISPR Therapeutics AG: SWOT Analysis Figure 180: Thermo Fisher Scientific, Inc.: Overall Product Portfolio Figure 181: Thermo Fisher Scientific, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 182: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020 Figure 183: Thermo Fisher Scientific, Inc.: Net Revenue (by Business Segment), $Million, 2018-2020 Figure 184: Thermo Fisher Scientific, Inc.: Net Revenue (by Region), $Million, 2018-2020 Figure 185: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 186: Thermo Fisher Scientific, Inc.: SWOT Analysis Figure 187: GeneCopoeia, Inc.: Overall Product Portfolio Figure 188: GeneCopoeia, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 189: GeneCopoeia, Inc.: SWOT Analysis Figure 190: GenScript Biotech Corporation: Overall Product Portfolio Figure 191: GenScript Biotech Corporation: CRISPR Gene Editing Product Portfolio Category Figure 192: GenScript Biotech Corporation: Overall Financials, $Million, 2018-2020 Figure 193: GenScript Biotech Corporation: Net Revenue (by Business Segment), $Million, 2018-2020 Figure 194: GenScript Biotech Corporation: Net Revenue (by Region), $Million, 2018-2020 Figure 195: GenScript Biotech Corporation: R&D Expenditure, $Million, 2018-2020 Figure 196: GenScript Biotech Corporation: SWOT Analysis Figure 197: Horizon Discovery Group PLC: Overall Product Portfolio Figure 198: Horizon Discovery Group PLC: CRISPR Gene Editing Product Portfolio Category Figure 199: Horizon Discovery Group PLC: Overall Financials, $Million, 2017-2019 Figure 200: Horizon Discovery Group PLC: Net Revenue (by Business Segment), $Million, 2017-2019 Figure 201: Horizon Discovery Group PLC: Net Revenue (by Region), $Million, 2017-2019 Figure 202: Horizon Discovery Group PLC: R&D Expenditure, $Million, 2017-2019 Figure 203: Horizon Discovery Group PLC: SWOT Analysis Figure 204: Integrated DNA Technologies, Inc.: Overall Product Portfolio Figure 205: Integrated DNA Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 206: Integrated DNA Technologies, Inc.: SWOT Analysis Figure 207: Merck KGaA: Overall Product Portfolio Figure 208: Merck KGaA: CRISPR Gene Editing Product Portfolio Category Figure 209: Merck KGaA: Overall Financials, $Million, 2018-2020 Figure 210: Merck KGaA: Net Revenue (by Business Segment), $Million, 2018-2020 Figure 211: Merck KGaA: Net Revenue (by Region), $Million, 2018-2020 Figure 212: Merck KGaA: R&D Expenditure, $Million, 2018-2020 Figure 213: Merck KGaA: SWOT Analysis Figure 214: New England Biolabs, Inc.: Overall Product Portfolio Figure 215: New England Biolabs, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 216: New England Biolabs, Inc.: SWOT Analysis Figure 217: Origene Technologies, Inc.: Overall Product Portfolio Figure 218: Origene Technologies, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 219: Origene Technologies, Inc.: SWOT Analysis Figure 220: Rockland Immunochemicals, Inc.: Overall Product Portfolio Figure 221: Rockland Immunochemicals, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 222: Rockland Immunochemicals, Inc.: SWOT Analysis Figure 223: Synthego Corporation: Overall Product Portfolio Figure 224: Synthego Corporation: CRISPR Gene Editing Product Portfolio Category Figure 225: Synthego Corporation: SWOT Analysis Figure 226: System Biosciences LLC: Overall Product Portfolio Figure 227: System Biosciences LLC: CRISPR Gene Editing Product Portfolio Category Figure 228: System Biosciences LLC: SWOT Analysis Figure 229: ToolGen, Inc.: Overall Product Portfolio Figure 230: ToolGen, Inc.: CRISPR Gene Editing Product Portfolio Category Figure 231: ToolGen, Inc.: SWOT Analysis Figure 232: Takara Bio: Overall Product Portfolio Figure 233: Takara Bio: CRISPR Gene Editing Product Portfolio Category Figure 234: Takara Bio: Overall Financials, $Million, 2018-2020 Figure 235: Takara Bio: Net Revenue (by Business Segment), $Million, 2018-2020 Figure 236: Takara Bio: Net Revenue (by Region), $Million, 2018-2020 Figure 237: Takara Bio: R&D Expenditure, $Million, 2018-2020 Figure 238: Takara Bio: SWOT Analysis